IBDEI27A ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,36937,2)
 ;;=^5001826
 ;;^UTILITY(U,$J,358.3,36938,0)
 ;;=C93.32^^169^1862^36
 ;;^UTILITY(U,$J,358.3,36938,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36938,1,3,0)
 ;;=3^Juvenile myelomonocytic leukemia,in relapse
 ;;^UTILITY(U,$J,358.3,36938,1,4,0)
 ;;=4^C93.32
 ;;^UTILITY(U,$J,358.3,36938,2)
 ;;=^5001827
 ;;^UTILITY(U,$J,358.3,36939,0)
 ;;=D48.0^^169^1863^5
 ;;^UTILITY(U,$J,358.3,36939,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36939,1,3,0)
 ;;=3^Neoplasm of uncertain behavior of bone/artic cartl
 ;;^UTILITY(U,$J,358.3,36939,1,4,0)
 ;;=4^D48.0
 ;;^UTILITY(U,$J,358.3,36939,2)
 ;;=^81953
 ;;^UTILITY(U,$J,358.3,36940,0)
 ;;=D48.1^^169^1863^6
 ;;^UTILITY(U,$J,358.3,36940,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36940,1,3,0)
 ;;=3^Neoplasm of uncertain behavior of connctv/soft tiss
 ;;^UTILITY(U,$J,358.3,36940,1,4,0)
 ;;=4^D48.1
 ;;^UTILITY(U,$J,358.3,36940,2)
 ;;=^267776
 ;;^UTILITY(U,$J,358.3,36941,0)
 ;;=D48.5^^169^1863^10
 ;;^UTILITY(U,$J,358.3,36941,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36941,1,3,0)
 ;;=3^Neoplasm of uncertain behavior of skin
 ;;^UTILITY(U,$J,358.3,36941,1,4,0)
 ;;=4^D48.5
 ;;^UTILITY(U,$J,358.3,36941,2)
 ;;=^267777
 ;;^UTILITY(U,$J,358.3,36942,0)
 ;;=D48.61^^169^1863^9
 ;;^UTILITY(U,$J,358.3,36942,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36942,1,3,0)
 ;;=3^Neoplasm of uncertain behavior of right breast
 ;;^UTILITY(U,$J,358.3,36942,1,4,0)
 ;;=4^D48.61
 ;;^UTILITY(U,$J,358.3,36942,2)
 ;;=^5002267
 ;;^UTILITY(U,$J,358.3,36943,0)
 ;;=D48.62^^169^1863^7
 ;;^UTILITY(U,$J,358.3,36943,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36943,1,3,0)
 ;;=3^Neoplasm of uncertain behavior of left breast
 ;;^UTILITY(U,$J,358.3,36943,1,4,0)
 ;;=4^D48.62
 ;;^UTILITY(U,$J,358.3,36943,2)
 ;;=^5002268
 ;;^UTILITY(U,$J,358.3,36944,0)
 ;;=D47.0^^169^1863^2
 ;;^UTILITY(U,$J,358.3,36944,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36944,1,3,0)
 ;;=3^Histiocytic and mast cell tumors of uncertain behavior
 ;;^UTILITY(U,$J,358.3,36944,1,4,0)
 ;;=4^D47.0
 ;;^UTILITY(U,$J,358.3,36944,2)
 ;;=^5002255
 ;;^UTILITY(U,$J,358.3,36945,0)
 ;;=D46.0^^169^1863^18
 ;;^UTILITY(U,$J,358.3,36945,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36945,1,3,0)
 ;;=3^Refractory anemia without ring sideroblasts, so stated
 ;;^UTILITY(U,$J,358.3,36945,1,4,0)
 ;;=4^D46.0
 ;;^UTILITY(U,$J,358.3,36945,2)
 ;;=^5002245
 ;;^UTILITY(U,$J,358.3,36946,0)
 ;;=D46.1^^169^1863^17
 ;;^UTILITY(U,$J,358.3,36946,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36946,1,3,0)
 ;;=3^Refractory anemia with ring sideroblasts
 ;;^UTILITY(U,$J,358.3,36946,1,4,0)
 ;;=4^D46.1
 ;;^UTILITY(U,$J,358.3,36946,2)
 ;;=^5002246
 ;;^UTILITY(U,$J,358.3,36947,0)
 ;;=D46.20^^169^1863^14
 ;;^UTILITY(U,$J,358.3,36947,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36947,1,3,0)
 ;;=3^Refractory anemia with excess of blasts, unspecified
 ;;^UTILITY(U,$J,358.3,36947,1,4,0)
 ;;=4^D46.20
 ;;^UTILITY(U,$J,358.3,36947,2)
 ;;=^5002247
 ;;^UTILITY(U,$J,358.3,36948,0)
 ;;=D46.21^^169^1863^15
 ;;^UTILITY(U,$J,358.3,36948,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36948,1,3,0)
 ;;=3^Refractory anemia with excess of blasts 1
 ;;^UTILITY(U,$J,358.3,36948,1,4,0)
 ;;=4^D46.21
 ;;^UTILITY(U,$J,358.3,36948,2)
 ;;=^5002248
 ;;^UTILITY(U,$J,358.3,36949,0)
 ;;=D46.A^^169^1863^19
 ;;^UTILITY(U,$J,358.3,36949,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36949,1,3,0)
 ;;=3^Refractory cytopenia with multilineage dysplasia
 ;;^UTILITY(U,$J,358.3,36949,1,4,0)
 ;;=4^D46.A
 ;;^UTILITY(U,$J,358.3,36949,2)
 ;;=^5002251
 ;;^UTILITY(U,$J,358.3,36950,0)
 ;;=D46.B^^169^1863^13
